PALVELLA THERAPEUTICS, INC. — fact timeline

Matthew Pauls was appointed as Class I director at PALVELLA THERAPEUTICS, INC..

“appointed Matthew Pauls, to serve as a Class I director”

PALVELLA THERAPEUTICS, INC. shareholders approved Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 5.

“Proposal 6 – Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 5. The stockholders approved an adjournment of the Annual Meeting to the extent there were insufficient votes to approve Proposal 5, but such an adjournment was not necessary in light of the approval of Proposal 5 at the Annual Meeting. The voting results for the adjournment proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 7,649,243 2,519,068 7,743 1,401,415”

PALVELLA THERAPEUTICS, INC. shareholders approved Approval of an amendment to the Palvella Therapeutics, Inc. 2024 Equity Incentive Plan to increase the authorized shares issuable thereunder by 750,000 shares.

“Proposal 5 – Approval of an amendment to the Palvella Therapeutics, Inc. 2024 Equity Incentive Plan to increase the authorized shares issuable thereunder by 750,000 shares. The stockholders approved the Plan Amendment, as follows: Votes For Votes Against Abstentions Broker Non-Votes 7,692,709 2,475,470 7,875 1,401,415”

PALVELLA THERAPEUTICS, INC. shareholders approved Approval, on an advisory basis, of the preferred frequency of future advisory votes on the compensation paid to the Company’s named executive officers.

“Proposal 4 - Approval, on an advisory basis, of the preferred frequency of future advisory votes on the compensation paid to the Company’s named executive officers. The stockholders approved, on an advisory basis, the preferred frequency of future advisory votes on compensation of the Company’s named executive officers, as follows: Every Year Every 2 Years Every 3 Years Abstain Broker Non-Votes 9,183,170 1,002 984,332 7,550 1,401,415”

PALVELLA THERAPEUTICS, INC. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers in 2025.

“Proposal 3 - Approval, on an advisory basis, of the compensation of the Company’s named executive officers in 2025. The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers in 2025, as follows: Votes For Votes Against Abstentions Broker Non-Votes 10,008,180 160,717 7,157 1,401,415”

PALVELLA THERAPEUTICS, INC. shareholders approved Ratification of Independent Registered Public Accountant.

“Proposal 2 - Ratification of Independent Registered Public Accountant. The appointment of Ernst &Young LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year was ratified, as follows: Votes For Votes Against Abstentions 11,557,687 13,216 6,566”

PALVELLA THERAPEUTICS, INC. shareholders approved Election of Class III Directors.

“Proposal 1 - Election of Class III Directors. George M. Jenkins, Todd C. Davis and John Doux, M.D . were elected to the Board as Class III directors to serve until the Company’s 2029 Annual Meeting of Stockholders and until their successors, if any, are duly elected and qualified or appointed, or their earlier death, resignation, retirement, disqualification or removal, as follows: Name Votes For Votes Withheld Broker Non-Votes George M. Jenkins 9,907,220 268,834 1,401,415 Todd C. Davis 8,321,303 1,854,751 1,401,415 John Doux, M.D. 9,958,528 217,526 1,401,415”

PALVELLA THERAPEUTICS, INC. reported financial results for the first quarter ending March 31, 2026.

“announced its financial results for the quarter ended March 31, 2026”

PALVELLA THERAPEUTICS, INC. reported financial results for full year ending December 31, 2025.

“On March 31, 2026, Palvella Therapeutics, Inc. (the “ Company ”) announced its financial results for the year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”

PALVELLA THERAPEUTICS, INC. entered into Underwriting Agreement with TD Securities (USA) LLC, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated valued at approximately $187.3 million (effective 2026-02-25).

“On February 25, 2026, Palvella Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated, as representatives (the “Representatives”) of the underwriters listed in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 1,600,000 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), at a price to the public of $125.00 (the “Offering”).”

PALVELLA THERAPEUTICS, INC.: As a result of the Merger, the Company ceased being a shell company (effective 2024-12-13).

“As a result of the Merger, the Company ceased being a shell company.”

PALVELLA THERAPEUTICS, INC.: The Company increased the number of authorized shares of common stock from 3,750,000 to 200,000,000 pursuant to an amendment to the Amended and Restated Articles of Incorporation (effective 2024-12-13).

“In connection with the consummation of the Merger, the Company increased the number of authorized shares of the Company’s common stock from 3,750,000 to 200,000,000 pursuant to an amendment to the Amended and Restated Articles of Incorporation of the Company.”

PALVELLA THERAPEUTICS, INC.: The Company amended its Amended and Restated Articles of Incorporation to change its name from Pieris Pharmaceuticals, Inc. to Palvella Therapeutics, Inc (effective 2024-12-13).

“In connection with the consummation of the Merger, the Company changed its name from "Pieris Pharmaceuticals, Inc." to "Palvella Therapeutics, Inc." pursuant to an amendment to the Amended and Restated Articles of Incorporation to the Company.”

PALVELLA THERAPEUTICS, INC. underwent a change of control involving Palvella Therapeutics, Inc., a Delaware corporation (closed 2024-12-13).

“On December 13, 2024, the Company completed the Merger in accordance with the terms of the Merger Agreement, pursuant to which, among other matters, subject to the terms and conditions thereof, Merger Sub merged with and into Former Palvella, with Former Palvella surviving as the surviving corporation and a wholly owned subsidiary of the Company.”

PALVELLA THERAPEUTICS, INC.: Increased authorized shares of common stock from 3,750,000 to 200,000,000 (effective 2024-12-12).

“At the Special Meeting, the Company’s stockholders approved an amendment to the amended and restated articles of incorporation of the Company (the “Authorized Share Increase Amendment”) to implement an increase in the number of authorized shares of common stock from 3,750,000 to 200,000,000 (the “Share Increase”). On December 12, 2024, the Company filed the Share Increase Amendment with the Nevada Secretary of State to effect the Share Increase effective on December 12, 2024.”

Shane Olwill departed as Senior Vice President and Chief Development Officer at PALVELLA THERAPEUTICS, INC..

“Pieris and Shane Olwill, Ph.D., Pieris’ Senior Vice President and Chief Development Officer, mutually agreed that in connection with the signing of the Merger Agreement, Dr. Olwill would step down effective October 31, 2024.”

PALVELLA THERAPEUTICS, INC.: Filing of Certificate of Change to effect a 1-for-80 reverse stock split of common stock and adjust authorized shares accordingly (effective 2024-04-22).

“The Company effected the Reverse Stock Split pursuant to the Company’s filing of a Certificate of Change (the “Certificate”) with the Nevada Secretary of State on April 18, 2024, in accordance with Nevada Revised Statutes (“ NRS ”) 78.209.”

PALVELLA THERAPEUTICS, INC. terminated Lease Termination Agreement with Hallbergmoos Grundvermögen GmbH valued at termination fee of approximately €9.7 million; remaining lease payments of approximately $18.4 milli (effective 2023-12-15).

“Item 1.02 Termination of a Material Definitive Agreement As previously disclosed, Pieris Pharmaceuticals GmbH ("Pieris GmbH"), a wholly owned subsidiary of Pieris Pharmaceuticals, Inc. (the "Company"), entered into a lease agreement with Hallbergmoos Grundvermögen GmbH ("Lessor") on October 24, 2018, which was subsequently amended on May 21, 2019, February 13, 2020 and May 19, 2020 (collectively, the "Lease Agreement").”

PALVELLA THERAPEUTICS, INC. announced a restructuring with charges of approximately $3.4 million affecting Workplace Restructuring.

“As a result of the Workplace Restructuring, the Company expects to incur estimated retention benefits, severance and related costs of approximately $3.4 million through the second quarter of 2024.”

PALVELLA THERAPEUTICS, INC. announced a restructuring with charges of approximately $3.4 million (approximately 70%).

“on July 17, 2023, the Board of Directors of the Company approved a reduction in force of the Company's workforce by approximately 70% to be substantially completed in the fourth quarter of 2023 (the "Workplace Reduction"). As a result of the Workplace Reduction, the Company expects to incur estimated severance and other employee termination-related costs of approximately $3.4 million in the third quarter 2023.”

Ahmed Mousa resigned as Senior Vice President, Chief Business Officer, General Counsel & Corporate Secretary at PALVELLA THERAPEUTICS, INC..

“On July 13, 2023, Ahmed Mousa, the Senior Vice President, Chief Business Officer, General Counsel & Corporate Secretary of Pieris Pharmaceuticals, Inc. (the “Company”), gave notice that he will resign from the Company effective September 11, 2023 in order to become chief executive officer of Vicore Pharma Holding AB.”

PALVELLA THERAPEUTICS, INC. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2023-06-21 meeting.

“5. Say on Pay Votes For Votes Against Votes Abstained Broker Non-Votes 17,227,404 2,828,509 5,556,466 19,231,424”

PALVELLA THERAPEUTICS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent auditor at the 2023-06-21 meeting.

“4. Auditor Ratification Votes For Votes Against Votes Abstained Broker Non-Votes 44,353,310 96,301 394,192 -”

PALVELLA THERAPEUTICS, INC. shareholders approved Approval of 2023 ESPP at the 2023-06-21 meeting.

“3. 2023 ESPP Approval Votes For Votes Against Votes Abstained Broker Non-Votes 19,672,797 410,705 5,528,877 19,231,424”

PALVELLA THERAPEUTICS, INC. shareholders approved Approval of amendment to the 2020 EIP at the 2023-06-21 meeting.

“2. 2020 EIP Amendment Approval Votes For Votes Against Votes Abstained Broker Non-Votes 18,811,753 6,306,669 493,957 19,231,424”

PALVELLA THERAPEUTICS, INC. shareholders approved Election of Directors at the 2023-06-21 meeting.

“1. Election of Directors Name Votes For Votes Withheld Broker Non-Votes Stephen S. Yoder 25,191,766 420,613 19,231,424 Michael Richman 23,534,942 2,077,437 19,231,424 Matthew L. Sherman, M.D. 25,191,653 420,726 19,231,424”

PALVELLA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 15, 2023, Pieris Pharmaceuticals, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), has fallen below $1.00 per share for 30 consecutive business days, the Company no longer meets the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). This Not”

PALVELLA THERAPEUTICS, INC. reported financial results for the quarter ended March 31, 2023.

“Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, reported financial results for the quarter ended March 31, 2023, and provided a business update.”

PALVELLA THERAPEUTICS, INC. reported financial results for fiscal year ended December 31, 2022.

“reported financial results for the fiscal year ended December 31, 2022, and provided a business update.”

PALVELLA THERAPEUTICS, INC. reported financial results for the third quarter of 2022 ended September 30, 2022.

“On November 2, 2022, Pieris Pharmaceuticals, Inc. (the “Company”) issued a press release announcing certain financial results for the quarter ended September 30, 2022.”

Tim Demuth departed as Senior Vice President and Chief Medical Officer at PALVELLA THERAPEUTICS, INC..

“On August 4, 2022, Pieris Pharmaceuticals, Inc. (together with its wholly-owned subsidiary, Pieris Pharmaceuticals GmbH, the " Company ") announced that Tim Demuth, M.D., Ph.D. has mutually agreed with the Company to step down effective September 30, 2022 ("Separation Date").”

Thomas Bures was appointed as Senior Vice President and Chief Financial Officer at PALVELLA THERAPEUTICS, INC..

“the Board appointed Mr. Thomas Bures, the Company’s Vice President, Finance and Treasurer, as Senior Vice President and Chief Financial Officer, effective as of October 6, 2021.”